BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal
Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ:
IPXL), today announced that Andrew S.
Boyer, 52, has joined Amneal as Executive Vice President,
Commercial Operations and is expected to serve in the same capacity
for the new combined company following the consummation of the
combination with Impax. Mr. Boyer most recently served as President
and CEO of North America Generics, Teva Pharmaceuticals, Inc.
"We are pleased that Andy has joined Amneal and will be leading
our commercial organization," said Chirag
Patel, Co-CEO and chairman, Amneal Pharmaceuticals. "Andy is
an accomplished executive with more than 20 years of pharmaceutical
experience architecting commercial strategies designed to
capitalize on changing customer needs and market opportunities. His
addition further enhances our current leadership team as well as
the proposed leadership team for the new Amneal."
Mr. Boyer will work closely with Chirag
and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future
CEO of the new Amneal, to further enhance its business in
preparation for the pending combination with Impax, which is
currently expected to occur in the first half of 2018.
Mr. Boyer commented, "I am excited to join Amneal at this
important time in the company's evolution and eventual combination
with Impax. Amneal has an exceptional generics portfolio and is
well regarded by customers for its quality, value and service. I
look forward to working with my new colleagues to build upon that
strong foundation and lead the combined organization's continued
advancement as a generic pharmaceuticals leader."
Prior to joining Teva, Mr. Boyer was Senior Vice President of
Sales and Marketing for the U.S. Generics Division at Allergan plc
(formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.)
since September of 2006. Mr. Boyer joined Allergan in 1998 as
Associate Director of Marketing in Generics. Before joining
Allergan, Mr. Boyer served as National Accounts Manager for
Lederle/American Cyanamid as well as Marketing Manager for Barr
Laboratories. He serves as a Director of Association for Accessible
Medicines. Mr. Boyer received his bachelor's degree in Business
Administration and Management from State
University of New York at Albany.
About Amneal
Amneal Pharmaceuticals LLC, a
privately-held company headquartered in Bridgewater, New Jersey, is one of the largest
and fastest growing generic pharmaceutical manufacturers in
the United States. Founded in
2002, Amneal now has more than 5,000 employees in its operations in
North America, Asia, and Europe, working together to bring
high-quality, affordable medicines to patients worldwide. Amneal
has significantly expanded its portfolio of generic products to
include complex dosage forms in a broad range of therapeutic areas.
For more information, visit www.amneal.com.
About Impax
Impax Laboratories, Inc. is a specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of central
nervous system disorder branded products. Impax markets its generic
products through its Impax Generics division and markets its
branded products through the Impax Specialty Pharma division.
Additionally, where strategically appropriate, Impax develops
marketing partnerships to fully leverage its technology platform
and pursues partnership opportunities that offer alternative dosage
form technologies, such as injectables, nasal sprays, inhalers,
patches, creams, and ointments. For more information, please visit
Impax's web site at: www.impaxlabs.com.
Additional Information and Where to Find It
This
communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval. This communication may be deemed to be
solicitation material in respect of the proposed transaction
between Impax Laboratories, Inc. ("Impax") and Amneal
Pharmaceuticals LLC ("Amneal") pursuant to the Business Combination
Agreement dated as of October 17,
2017 by and among Impax, Amneal, Atlas Holdings, Inc.
("Holdco"), and K2 Merger Sub Corporation as amended by Amendment
No. 1, dated November 21, 2017 and Amendment No. 2 dated
December 16, 2017. In connection with
the proposed transaction, Holdco filed a registration statement on
Form S-4, containing a preliminary proxy statement/prospectus, with
the Securities and Exchange Commission ("SEC") on November 21,
2017. A definitive proxy statement/prospectus will be delivered as
required by applicable law after the registration statement on Form
S-4 is declare effective by the SEC. This communication is not a
substitute for the registration statement, definitive proxy
statement/prospectus or any other documents that Impax or Holdco
has filed or may file with the SEC or send to stockholders in
connection with the proposed business combination. INVESTORS AND
SECURITY HOLDERS OF IMPAX ARE URGED TO READ ALL RELEVANT DOCUMENTS
FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT/PROSPECTUS,
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION.
Investors and security holders will be able to obtain copies of
the registration statement, including the proxy
statement/prospectus and other documents filed with the SEC (when
available) free of charge at the SEC's website, http://www.sec.gov.
Copies of the documents filed with the SEC by Impax or Holdco will
be available free of charge on Impax's internet website at
http://www.impaxlabs.com or by contacting Mark Donohue, Investor Relations and Corporate
Communications at (215) 558-4526.
Forward-Looking Statements
This communication
includes "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are based on our
beliefs and assumptions. These forward-looking statements are
identified by terms and phrases such as: anticipate, believe,
intend, estimate, expect, continue, should, could, may, plan,
project, predict, will, target, potential, forecast, and the
negative thereof and similar expressions. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain, such as statements about the potential timing
or consummation of the proposed transaction or the anticipated
benefits thereof, including, without limitation, future financial
and operating results. Impax cautions readers that these and other
forward-looking statements are not guarantees of future results and
are subject to risks, uncertainties and assumptions that could
cause actual results to differ materially from those expressed in
any forward-looking statements. Important risk factors that could
cause actual results to differ materially from those indicated in
any forward-looking statement include, but are not limited to: (i)
the ability to obtain shareholder and regulatory approvals, or the
possibility that they may delay the transaction or that such
regulatory approval may result in the imposition of conditions that
could cause the parties to abandon the transaction, (ii) the risk
that a condition to effecting the transaction may not be satisfied;
(iii) the ability of Impax and Amneal to integrate their businesses
successfully and to achieve anticipated synergies, (iv) the
possibility that other anticipated benefits of the proposed
transaction will not be realized, including without limitation,
anticipated revenues, expenses, earnings and other financial
results, and growth and expansion of the new combined company's
operations, and the anticipated tax treatment, (v) potential
litigation relating to the proposed transaction that could be
instituted against Impax, Amneal or their respective directors,
(vi) possible disruptions from the proposed transaction that could
harm Impax's and/or Amneal's business, including current plans and
operations, (vii) the ability of Impax or Amneal to retain, attract
and hire key personnel, (viii) potential adverse reactions or
changes to relationships with clients, employees, suppliers or
other parties resulting from the announcement or completion of the
transaction, (ix) potential business uncertainty, including changes
to existing business relationships, during the pendency of the
business combination that could affect Impax's or Amneal's
financial performance, (x) certain restrictions during the pendency
of the transaction that may impact Impax's or Amneal's ability to
pursue certain business opportunities or strategic transactions,
(xi) continued availability of capital and financing and rating
agency actions, (xii) legislative, regulatory and economic
developments; (xiii) unpredictability and severity of catastrophic
events, including, but not limited to, acts of terrorism or
outbreak of war or hostilities, as well as management's response to
any of the aforementioned factors; and (xiv) such other factors as
are set forth in Impax's periodic public filings with the SEC,
including but not limited to those described under the headings
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Information" in Impax's Form 10-K for the fiscal year ended
December 31, 2016, in the Form S-4
filed by Holdco and in Impax's other filings made with the SEC from
time to time, which are available via the SEC's website at
www.sec.gov. While the list of factors presented here is, and the
list of factors to be presented in the proxy statement are,
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward looking statements. Consequences of
material differences in results as compared with those anticipated
in the forward-looking statements could include, among other
things, business disruption, operational problems, financial loss,
legal liability to third parties and similar risks, any of which
could have a material adverse effect on Impax's or Amneal's
consolidated financial condition, results of operations, credit
rating or liquidity. In light of these risks, uncertainties and
assumptions, the events described in the forward-looking statements
might not occur or might occur to a different extent or at a
different time than Impax has described. All such factors are
difficult to predict and beyond our control. All forward-looking
statements included in this document are based upon information
available to Impax on the date hereof, and unless legally required,
Impax disclaims and does not undertake any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Participants in Solicitation
Impax, Amneal, Holdco
and their respective directors and executive officers may be deemed
to be participants in the solicitation of proxies from Impax's
stockholders in respect of the proposed transaction. Information
about the directors and executive officers of Impax is set forth in
its proxy statement for its 2017 annual meeting of stockholders,
which was filed with the SEC on April 5,
2017, and in its Annual Report on Form 10-K for the year
ended Dec. 31, 2016. Other
information regarding the participants in the proxy solicitations
and a description of their direct and indirect interests, by
security holdings or otherwise, is contained in the proxy
statement/prospectus regarding the proposed transaction and other
relevant materials filed and to be filed with the SEC when they
become available. You may obtain free copies of these documents as
described in the preceding paragraph. This communication is not
intended to and shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities or a solicitation of any vote of approval, nor
shall there be any sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended.
CONTACTS:
Amneal
Apurva
Saraf
(631) 742-7674
Impax
Mark
Donohue
(215) 558-4526
View original
content:http://www.prnewswire.com/news-releases/andrew-s-boyer-joins-amneal-pharmaceuticals-as-executive-vice-president-commercial-operations-300593769.html
SOURCE Impax Laboratories, Inc.; Amneal Pharmaceuticals LLC